Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Blood Cancer Discovery|December 12, 2024
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell LymphomaDanny Luan, Susan DeWolf, Teng Fei, et al.
Blood Advances|August 12, 2020
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Haematologica|November 21, 2024
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.
Bone Marrow Transplantation|February 1, 2025
Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphomaMagdalena Corona, Andrew Ip, Samantha Brown, et al.
Transplantation and Cellular Therapy|August 9, 2022
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell LymphomaKarthik Nath, Ana Alarcon Tomas, Jessica Flynn, et al.
Blood Advances|March 7, 2022
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomasManit Munshi, Xia Liu, Amanda Kofides, et al.
Blood|September 7, 2017
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Heiko Schöder, Somali Gavane, et al.
Pageof 12